Immuneering $IMRX Surges 17% After Insider Stock Purchases
A spate of insider share purchases at Immuneering has sparked intrigue, suggesting internal confidence amidst its precarious financial backdrop. With its lead drug, IMM-1-104, potentially stirring hope for RAS-mutant cancer...